These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 18495444)

  • 1. Reversible pegylation of insulin facilitates its prolonged action in vivo.
    Shechter Y; Mironchik M; Rubinraut S; Tsubery H; Sasson K; Marcus Y; Fridkin M
    Eur J Pharm Biopharm; 2008 Sep; 70(1):19-28. PubMed ID: 18495444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible pegylation prolongs the hypotensive effect of atrial natriuretic peptide.
    Nesher M; Vachutinsky Y; Fridkin G; Schwarz Y; Sasson K; Fridkin M; Shechter Y; Lichtstein D
    Bioconjug Chem; 2008 Jan; 19(1):342-8. PubMed ID: 18069777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin.
    Shechter Y; Mironchik M; Rubinraut S; Saul A; Tsubery H; Fridkin M
    Bioconjug Chem; 2005; 16(4):913-20. PubMed ID: 16029032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: a study with gentamicin.
    Marcus Y; Sasson K; Fridkin M; Shechter Y
    J Med Chem; 2008 Jul; 51(14):4300-5. PubMed ID: 18578475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period.
    Peleg-Shulman T; Tsubery H; Mironchik M; Fridkin M; Schreiber G; Shechter Y
    J Med Chem; 2004 Sep; 47(20):4897-904. PubMed ID: 15369394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel approach for a water-soluble long-acting insulin prodrug: design, preparation, and analysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl](3)-insulin.
    Gershonov E; Goldwaser I; Fridkin M; Shechter Y
    J Med Chem; 2000 Jun; 43(13):2530-7. PubMed ID: 10891112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.
    Sasson K; Marcus Y; Lev-Goldman V; Rubinraut S; Fridkin M; Shechter Y
    J Control Release; 2010 Mar; 142(2):214-20. PubMed ID: 19883707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopharmaceutical characterisation of insulin and recombinant human growth hormone loaded lipid submicron particles produced by supercritical gas micro-atomisation.
    Salmaso S; Bersani S; Elvassore N; Bertucco A; Caliceti P
    Int J Pharm; 2009 Sep; 379(1):51-8. PubMed ID: 19545616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-induced release of glycosylpoly(ethylene glycol) insulin bound to a soluble conjugate of concanavalin A.
    Liu F; Song SC; Mix D; Baudys M; Kim SW
    Bioconjug Chem; 1997; 8(5):664-72. PubMed ID: 9327129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation and characterization of an oily-based system for oral delivery of insulin.
    Elsayed A; Remawi MA; Qinna N; Farouk A; Badwan A
    Eur J Pharm Biopharm; 2009 Oct; 73(2):269-79. PubMed ID: 19508890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats.
    Xia CQ; Wang J; Shen WC
    J Pharmacol Exp Ther; 2000 Nov; 295(2):594-600. PubMed ID: 11046093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and characterization of monomethoxypoly(ethylene glycol)-insulin conjugates.
    Zhang M; Dou H; Yin L; Zhang Y; Zhu S; Yin C
    Pharmazie; 2009 Mar; 64(3):190-6. PubMed ID: 19348342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis.
    Hinds KD; Campbell KM; Holland KM; Lewis DH; Piché CA; Schmidt PG
    J Control Release; 2005 Jun; 104(3):447-60. PubMed ID: 15911045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged antidiabetic effect of zinc-crystallized insulin loaded glycol chitosan nanoparticles in type 1 diabetic rats.
    Jo HG; Min KH; Nam TH; Na SJ; Park JH; Jeong SY
    Arch Pharm Res; 2008 Jul; 31(7):918-23. PubMed ID: 18704336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood glucose profiles in diabetic rodents using different insulin preparations.
    Schneider S; Weber R; Luippold G
    Arzneimittelforschung; 2004; 54(12):842-6. PubMed ID: 15646368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticulate delivery system for insulin: design, characterization and in vitro/in vivo bioactivity.
    Reis CP; Ribeiro AJ; Houng S; Veiga F; Neufeld RJ
    Eur J Pharm Sci; 2007 Apr; 30(5):392-7. PubMed ID: 17280820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo study of poly(ethylene glycol) conjugated ketoprofen to extend the duration of action.
    Choi HK; Chun MK; Lee SH; Jang MH; Kim HD; Jung CS; Oh SY
    Int J Pharm; 2007 Aug; 341(1-2):50-7. PubMed ID: 17517483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclodextrin complexed insulin encapsulated hydrogel microparticles: An oral delivery system for insulin.
    Sajeesh S; Bouchemal K; Marsaud V; Vauthier C; Sharma CP
    J Control Release; 2010 Nov; 147(3):377-84. PubMed ID: 20727924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesicles from Pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery.
    Xiong XY; Li YP; Li ZL; Zhou CL; Tam KC; Liu ZY; Xie GX
    J Control Release; 2007 Jul; 120(1-2):11-7. PubMed ID: 17509718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
    Youn YS; Lee KC
    Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.